Day: June 26, 2021

Bagsværd, Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic® (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic® 1.0 mg1. These data were the outcome of the SUSTAIN FORTE trial, a phase 3b, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs Ozempic® 1.0 mg as add-on to metformin with or without sulfonylureas in 961 adults with type 2 diabetes in need of additional blood sugar reduction. The results were presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA)1,2 and primary results are in press for publication in The Lancet Diabetes & Endocrinology. The trial met its primary endpoint, where people treated with once-weekly semaglutide 2.0 mg...

Intellia Therapeutics LogoIntellia Therapeutics LogoJohn Leonard, M.D., President and CEO, Intellia TherapeuticsJohn Leonard, M.D., President and CEO, Intellia TherapeuticsAbout Transthyretin (ATTR) AmyloidosisAbout Transthyretin (ATTR) AmyloidosisHow NTLA-2001 WorksHow NTLA-2001 WorksRegeneron Pharmaceuticals LogoRegeneron Pharmaceuticals LogoFirst-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response Encouraging safety profile; no serious adverse events observed in the first six patients by day 28 Data published...

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a primate without immune suppression represents a key step toward widespread treatment of disease using engineered cells SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs). The transplanted cells were induced pluripotent stem cells (iPSCs) with Sana’s hypoimmune gene modifications that enable immune evasion. Data were presented by Sonja Schrepfer, M.D., Ph.D., Head of Hypoimmune Platform at Sana, during the plenary...

AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects, and increased HBV-specific immune responses in 3/5 evaluable subjects AB-729 resulted in decreases in HBV RNA and all HBsAg isoforms demonstrating broad target engagement AB-729 dosed for 48 weeks continued to demonstrate a favorable safety and tolerability profile AB-836 pre-clinical data suggest the potential for increased efficacy and an enhanced resistance profile relative to previous generation capsid inhibitors Conference Call and Webcast Scheduled for 8:00 AM ET, Monday, June 28th, 2021 WARMINSTER, Pa., June 26, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical...

VANCOUVER, British Columbia, June 25, 2021 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) is pleased to announce the successful completion of its previously announced rights offering (the “Rights Offering”), which expired at 2:00 p.m. (Pacific Time) today. The Company will issue a total of 12,853,267 common shares in the Rights Offering for gross proceeds of approximately $60.4 million. The Company will issue a total of 10,992,281 common shares under basic subscription privileges in the Rights Offering and a total of 1,860,986 common shares under additional subscription privileges. To the knowledge of the Company, no person will become an insider as a result of the Rights Offering. The total number of issued and outstanding common shares of the Company upon completion of the Rights Offering will be 141,392,191. The...